You just read:

ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer

News provided by

The Janssen Pharmaceutical Companies of Johnson & Johnson

Feb 14, 2018, 03:56 EST